Verrica Pharmaceuticals (VRCA) to Release Earnings on Tuesday

Key Points

• Verrica Pharmaceuticals (VRCA) is expected to announce its Q2 2025 earnings on August 13th, with analysts predicting a loss of $0.10 per share and revenue of $4.37 million.
• The company's stock opened at $5.60 and has a market capitalization of $51.80 million, with a 52-week range between $3.82 and $58.20.
• Analysts maintain a consensus rating of "Hold" for Verrica Pharmaceuticals, with five holding and one buy rating, while the average target price is set at $80.00.

Verrica Pharmaceuticals (NASDAQ:VRCA - Get Free Report) is projected to announce its Q2 2025 earnings results after the market closes on Tuesday, August 12th. Analysts expect the company to announce earnings of ($0.10) per share and revenue of $4.37 million for the quarter.

Verrica Pharmaceuticals (NASDAQ:VRCA - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($1.00) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.40) by $0.40. The business had revenue of $3.44 million for the quarter, compared to the consensus estimate of $2.53 million. On average, analysts expect Verrica Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Verrica Pharmaceuticals Trading Up 3.9%

Shares of VRCA traded up $0.24 during trading hours on Friday, reaching $6.35. 10,701 shares of the company's stock traded hands, compared to its average volume of 41,826. The stock has a market cap of $58.74 million, a PE ratio of -0.53 and a beta of 1.92. The firm's 50 day simple moving average is $6.56 and its 200-day simple moving average is $6.07. Verrica Pharmaceuticals has a 12 month low of $3.82 and a 12 month high of $58.20.

Institutional Investors Weigh In On Verrica Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of VRCA. Goldman Sachs Group Inc. increased its holdings in shares of Verrica Pharmaceuticals by 23.3% in the first quarter. Goldman Sachs Group Inc. now owns 139,055 shares of the company's stock worth $61,000 after purchasing an additional 26,308 shares during the last quarter. Invesco Ltd. increased its holdings in shares of Verrica Pharmaceuticals by 64.8% in the first quarter. Invesco Ltd. now owns 74,388 shares of the company's stock worth $33,000 after purchasing an additional 29,256 shares during the last quarter. AQR Capital Management LLC increased its holdings in shares of Verrica Pharmaceuticals by 306.7% in the first quarter. AQR Capital Management LLC now owns 58,711 shares of the company's stock worth $26,000 after purchasing an additional 44,275 shares during the last quarter. Finally, Bank of America Corp DE increased its holdings in shares of Verrica Pharmaceuticals by 347.5% in the fourth quarter. Bank of America Corp DE now owns 143,818 shares of the company's stock worth $101,000 after purchasing an additional 111,678 shares during the last quarter. 42.45% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages recently weighed in on VRCA. Needham & Company LLC restated a "hold" rating on shares of Verrica Pharmaceuticals in a report on Wednesday, May 14th. Wall Street Zen raised Verrica Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Five research analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $80.00.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.